Cleaved-MMP17 (Q129) Antibody

What is Cleaved-MMP17 (Q129) Antibody and what epitope does it recognize?

Cleaved-MMP17 (Q129) Antibody is a specialized immunological reagent designed to detect endogenous levels of activated MMP-17 protein fragments that result specifically from cleavage adjacent to the glutamine residue at position 129 (Q129). This antibody is available in both monoclonal (mouse-derived) and polyclonal (rabbit-derived) formats . The antibody recognizes an epitope within the amino acid range 110-159 of human MMP17 , making it highly specific for detecting the cleaved form rather than the full-length protein.

The specificity of this antibody is particularly valuable for researchers interested in distinguishing between inactive precursor and active forms of MMP-17. By binding only to the cleaved fragment, this antibody enables researchers to monitor MMP-17 activation status in various experimental contexts, providing insight into the protein's functional state rather than merely its presence.

What is the structure and function of MMP17 in normal cellular processes?

Matrix metalloproteinase-17 (MMP17), also known as MT4-MMP or membrane-type-4 matrix metalloproteinase, is a membrane-bound zinc-dependent endopeptidase that belongs to the broader MMP family. Unlike some other MMPs, MMP17 is anchored to the cell membrane via a GPI-anchor on the extracellular side .

MMP17 functions primarily as an endopeptidase that degrades various components of the extracellular matrix, with a particular affinity for fibrin . Unlike some other matrix metalloproteinases, MMP17 does not hydrolyze collagen types I, II, III, IV, and V, gelatin, fibronectin, laminin, decorin, or alpha1-antitrypsin . This selective substrate specificity suggests a specialized role in tissue remodeling.

A key function of MMP17 appears to be its involvement in the activation of membrane-bound precursors of growth factors and inflammatory mediators. Notably, MMP17 cleaves pro-TNF-alpha at the 74-Ala-|-Gln-75 site , potentially participating in inflammatory signaling cascades. Additionally, MMP17 may be involved in tumoral processes, though its exact role in cancer progression remains an area of active investigation.

At the molecular level, MMP17 contains a conserved cysteine in the cysteine-switch motif that binds to the catalytic zinc ion, inhibiting the enzyme in its precursor form. The dissociation of this cysteine from the zinc ion upon activation-peptide release activates the enzyme , a common mechanism among MMPs.

How is MMP17 expressed in different tissues and cell types?

MMP17 exhibits a distinctive tissue expression pattern that provides clues about its physiological roles. According to the available research data, MMP17 is expressed in multiple tissues including:

• Brain

• Leukocytes

• Colon

• Ovary

• Testis

• Breast cancer tissue

Additionally, MMP17 expression has been observed in many transformed and non-transformed cell types , suggesting that it may play a general role in cellular processes across different tissues.

This diverse expression pattern indicates that MMP17 likely contributes to various physiological processes beyond simple matrix degradation. Its presence in brain tissue suggests potential roles in neural development or plasticity, while expression in leukocytes points to possible functions in immune responses. The expression in reproductive tissues (ovary and testis) may indicate roles in reproductive biology, and its presence in breast cancer tissue highlights potential involvement in pathological processes.

What are the validated applications for Cleaved-MMP17 (Q129) Antibody?

The Cleaved-MMP17 (Q129) Antibody has been validated for specific laboratory applications, with consistent results across different manufacturers. Based on the compiled research data, the primary validated applications include:

While these represent the currently validated applications, researchers should note that other applications such as immunohistochemistry (IHC), immunocytochemistry (ICC), and immunoprecipitation (IP) have not been extensively tested according to the available data . When exploring novel applications, preliminary validation experiments with appropriate controls are strongly recommended.

For Western Blot applications, the antibody typically detects a band of approximately 53 kDa , corresponding to the cleaved form of MMP17. This information is crucial for result interpretation and validation of antibody specificity in experimental contexts.

What are the best protocols for using Cleaved-MMP17 (Q129) Antibody in Western Blotting?

When conducting Western Blot analysis with Cleaved-MMP17 (Q129) Antibody, researchers should follow this optimized protocol based on consolidated research experience:

Sample Preparation:

• Extract total protein from cells or tissues using a standard lysis buffer containing protease inhibitors to prevent artificial degradation of MMP17.

• Quantify protein concentration using a reliable method such as BCA or Bradford assay.

• Prepare samples by mixing with Laemmli buffer and denaturing at 95°C for 5 minutes.

Gel Electrophoresis and Transfer:

• Load 20-50 μg of protein per lane on a 10-12% SDS-PAGE gel.

• Perform electrophoresis at 100-120V until adequate separation is achieved.

• Transfer proteins to a PVDF membrane (preferred over nitrocellulose for metalloproteinases) at 100V for 60-90 minutes or overnight at 30V.

Antibody Incubation:

• Block the membrane with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature.

• Incubate with Cleaved-MMP17 (Q129) Antibody at a dilution of 1:500 to 1:2000 in blocking buffer overnight at 4°C .

• Wash three times with TBST, 5 minutes each.

• Incubate with appropriate HRP-conjugated secondary antibody (anti-mouse for monoclonal or anti-rabbit for polyclonal variants) at 1:5000 dilution for 1 hour at room temperature.

• Wash three times with TBST, 5 minutes each.

Detection:

• Apply ECL substrate and develop using a digital imaging system or X-ray film.

• The expected band for cleaved MMP17 should appear at approximately 53 kDa .

Critical Considerations:

• Include positive controls such as lysates from A549 cells treated with etoposide (25 μM for 1 hour), which has been shown to induce MMP17 cleavage .

• For validation of specificity, consider including a blocking peptide control where the antibody is pre-incubated with the immunizing peptide before application to the membrane .

How should researchers prepare samples for optimal detection of cleaved MMP17?

Optimal detection of cleaved MMP17 requires careful consideration of sample preparation methods to preserve the native state of the cleaved protein while maximizing signal-to-noise ratio:

Cell Culture Samples:

• For enrichment of cleaved MMP17, consider treatments that induce proteolytic processing:

  • Etoposide treatment (25 μM for 1 hour) has been demonstrated to increase detectable levels of cleaved MMP17 in A549 cells .

  • TNF-alpha pathway activators may also increase MMP17 cleavage due to their functional relationship.

• Harvest cells directly into ice-cold lysis buffer containing:

  • 50 mM Tris-HCl (pH 7.4)

  • 150 mM NaCl

  • 1% Triton X-100

  • 0.5% sodium deoxycholate

  • Complete protease inhibitor cocktail

  • 1-2 mM EDTA (to inhibit metalloproteinase activity and prevent artificial cleavage)

• Maintain samples at 4°C throughout processing to minimize artifactual proteolysis.

Tissue Samples:

• Flash-freeze tissues immediately after collection in liquid nitrogen.

• Homogenize frozen tissues in the above lysis buffer using a mechanical homogenizer.

• Centrifuge homogenates at 14,000 × g for 15 minutes at 4°C to remove debris.

• Collect supernatant and determine protein concentration.

Critical Considerations:

• Avoid repeated freeze-thaw cycles as this may affect protein integrity.

• For membrane-associated forms of MMP17, consider using specialized membrane protein extraction kits that can efficiently solubilize GPI-anchored proteins.

• When studying cleaved forms specifically, remember that MMP17 undergoes processing by furin , so furin inhibitors may alter the detection pattern if added during cell culture.

What controls should be included when working with Cleaved-MMP17 (Q129) Antibody?

Implementing appropriate controls is essential for ensuring the validity and reproducibility of results when working with Cleaved-MMP17 (Q129) Antibody:

Positive Controls:

• A549 cell lysates treated with etoposide (25 μM, 1 hour) have been validated to show positive detection of cleaved MMP17 .

• Cell lines known to highly express MMP17, particularly those from brain, leukocytes, colon, ovary, testis, or breast cancer tissues .

Negative Controls:

• Lysates from cell lines with confirmed low or absent MMP17 expression.

• Primary antibody omission control (incubation with antibody diluent only).

Specificity Controls:

• Peptide competition/blocking control - pre-incubate the antibody with excess immunizing peptide (derived from human MMP17, AA range 110-159) before application to the membrane or cells. This should abolish or significantly reduce specific staining .

• siRNA knockdown of MMP17 in a positive cell line - this should reduce signal in proportion to knockdown efficiency.

Cross-Reactivity Assessment:

• If studying non-human samples, include human samples as reference standards since the antibody was raised against human MMP17 sequences, although cross-reactivity with mouse and rat has been reported .

Processing Controls:

• Include samples treated with furin inhibitors to demonstrate reduced levels of cleaved MMP17, as furin is involved in the proteolytic processing of MMP17 .

Loading Controls:

• Standard housekeeping proteins (β-actin, GAPDH, etc.) for Western blot normalization.

The table below summarizes the key controls and their expected outcomes:

How can researchers distinguish between cleaved and uncleaved forms of MMP17?

Distinguishing between cleaved and uncleaved forms of MMP17 requires strategic experimental approaches that take advantage of the structural and functional differences between these forms:

Antibody Selection Strategy:

• Use Cleaved-MMP17 (Q129) Antibody specifically for detecting the activated form resulting from cleavage adjacent to Q129 .

• In parallel experiments, use antibodies targeting different epitopes of MMP17, such as those recognizing:

  • The N-terminal pro-domain (present only in uncleaved forms)

  • The C-terminal domain (present in both forms, serving as a total MMP17 indicator)

Molecular Weight Discrimination:
The expected molecular weights for different forms provide crucial identification markers:

• Cleaved MMP17: Approximately 53 kDa

• Full-length pro-MMP17: Approximately 63-67 kDa

Functional Assays to Confirm Activation Status:

• Zymography techniques using MMP17 substrates can confirm enzymatic activity, which should correlate with the presence of cleaved forms.

• Co-immunoprecipitation with known MMP17 substrates (e.g., pro-TNF-alpha) can indicate functional activation.

Subcellular Fractionation:
Different forms of MMP17 may have distinct subcellular localizations:

• Cleaved, active forms may be more abundant in membrane fractions for the GPI-anchored isoform .

• Secreted forms may be detected in conditioned media for soluble variants.

Induction of Cleavage:
Compare samples with and without treatments known to induce MMP17 cleavage:

• Etoposide treatment (25 μM, 1 hour) has been demonstrated to increase levels of cleaved MMP17 .

• Furin overexpression should increase cleaved forms, as furin is involved in MMP17 processing .

2D Gel Electrophoresis:
This technique can separate proteins based on both molecular weight and isoelectric point, potentially allowing for better discrimination between cleaved and uncleaved forms that may have similar molecular weights but different charges.

Using these approaches in combination provides a robust framework for distinguishing between the different forms of MMP17 and validating the specificity of the Cleaved-MMP17 (Q129) Antibody in experimental contexts.

What are common technical challenges when working with Cleaved-MMP17 (Q129) Antibody?

Researchers working with Cleaved-MMP17 (Q129) Antibody may encounter several technical challenges that can impact experimental outcomes. Understanding and addressing these challenges proactively can significantly improve results:

Challenge 1: Low Signal Intensity

• Potential Causes: Insufficient protein, inadequate antibody concentration, low expression of cleaved MMP17, protein degradation during sample preparation.

• Solutions:

  • Increase protein loading (40-60 μg per lane)

  • Optimize antibody concentration (try 1:500 dilution for Western blot)

  • Enhance chemiluminescence detection using longer exposure times or more sensitive substrates

  • Enrich for membrane fractions when studying GPI-anchored isoforms

Challenge 2: High Background Signal

• Potential Causes: Insufficient blocking, excessive primary or secondary antibody concentration, inadequate washing.

• Solutions:

  • Extend blocking time to 2 hours or overnight at 4°C

  • Use alternative blocking agents (try 5% BSA instead of milk)

  • Increase washing duration and number of wash steps

  • Dilute antibody in fresh blocking buffer

Challenge 3: Multiple Bands or Unexpected Banding Patterns

• Potential Causes: Cross-reactivity with other MMPs, detection of different isoforms or degradation products, non-specific binding.

• Solutions:

  • Validate specificity using peptide competition assays

  • Compare results with knockout/knockdown controls

  • Use gradient gels for better separation of closely sized proteins

  • Consider native vs. reduced conditions to account for structural conformations

Challenge 4: Inconsistent Results Across Experiments

• Potential Causes: Variations in sample preparation, unstable antibody, inconsistent transfer efficiency.

• Solutions:

  • Standardize lysate preparation protocols

  • Aliquot antibodies to avoid repeated freeze-thaw cycles

  • Include consistent positive controls in each experiment

  • Monitor and normalize transfer efficiency using total protein staining

Challenge 5: Difficulties Detecting Cleaved MMP17 in Tissue Samples

• Potential Causes: Low abundance, masked epitopes, tissue-specific inhibitors.

• Solutions:

  • Implement epitope retrieval techniques

  • Consider immunoprecipitation before Western blotting to concentrate the target

  • Test multiple lysis conditions to optimize extraction from different tissues

  • Focus on tissues with known higher expression (brain, leukocytes, colon, ovary, testis, breast cancer)

A troubleshooting table summarizing key issues and interventions:

How does post-translational processing affect MMP17 detection?

Post-translational processing of MMP17 significantly impacts its detection using the Cleaved-MMP17 (Q129) Antibody, as this antibody specifically recognizes the cleaved form resulting from proteolytic processing. Understanding these modifications is crucial for accurate experimental design and data interpretation:

Furin-Mediated Processing:
MMP17 undergoes proteolytic processing by furin endopeptidase , which cleaves the pro-domain and contributes to enzyme activation. This processing:

• Generates the cleaved form recognized by the Cleaved-MMP17 (Q129) Antibody

• Alters the molecular weight from approximately 63-67 kDa (pro-form) to 53 kDa (cleaved form)

• May occur at different efficiencies across cell types, depending on furin expression levels

GPI-Anchor Modification:
The long isoform of MMP17 contains a GPI-anchor modification that localizes it to the cell membrane :

• This modification affects protein extraction efficiency during sample preparation

• Requires specialized lysis buffers containing detergents effective for GPI-anchored proteins

• May result in differential mobility on SDS-PAGE compared to predicted molecular weights

Zinc Binding and Cysteine Switch:
MMP17 contains a conserved cysteine in the cysteine-switch motif that binds catalytic zinc:

• This interaction inhibits the enzyme in its precursor form

• Dissociation of the cysteine from zinc upon activation-peptide release activates the enzyme

• The conformational change resulting from this switch may affect epitope accessibility

Calcium Binding:
MMP17 binds calcium as a cofactor , which may:

• Induce conformational changes affecting antibody recognition

• Stabilize certain protein conformations

• Influence protein-protein interactions that could mask epitopes

Experimental Implications and Recommendations:

• Modulating Furin Activity:

  • Furin inhibitors can be used to experimentally manipulate the ratio of cleaved to uncleaved MMP17

  • Overexpression of furin may increase cleaved MMP17 detection

  • Cell types with different basal furin expression may show variable cleaved MMP17 levels

• Sample Preparation Considerations:

  • Include 1-2 mM EDTA in lysis buffers to chelate zinc and calcium, potentially affecting conformation

  • For membrane-bound forms, use detergents effective for GPI-anchored proteins (Triton X-100, NP-40)

  • Processing samples at 4°C helps preserve the native state of post-translational modifications

• Activation Induction:

  • Etoposide treatment (25 μM, 1 hour) has been shown to induce MMP17 cleavage , providing a useful positive control

  • Other cellular stressors may similarly affect MMP17 processing and should be standardized in experimental protocols

• Cross-Reactivity Considerations:

  • Post-translational processing may differ between species, potentially affecting cross-reactivity

  • When working with mouse or rat samples, preliminary validation is recommended despite reported cross-reactivity

Understanding these post-translational modifications provides a framework for optimizing detection of cleaved MMP17 and interpreting variations in experimental results across different biological contexts.

How should researchers interpret varying band intensities in Western Blots with Cleaved-MMP17 (Q129) Antibody?

Interpreting band intensity variations in Western blots using Cleaved-MMP17 (Q129) Antibody requires careful consideration of both technical and biological factors that may influence results:

Quantitative Analysis Framework:

• Normalization Strategies:

  • Normalize cleaved MMP17 signal to appropriate loading controls (β-actin, GAPDH, or total protein stain)

  • For membrane proteins like MMP17, consider normalizing to membrane-specific markers (Na⁺/K⁺-ATPase, pan-cadherin) for more accurate comparison

  • When possible, normalize to total MMP17 levels (using a separate pan-MMP17 antibody) to distinguish changes in cleavage from changes in expression

• Signal Quantification Methods:

  • Use digital imaging systems with linear dynamic range for signal capture

  • Ensure exposures are within the linear range of detection (avoid saturated pixels)

  • Apply consistent analysis parameters across all blots in a study

  • Perform triplicate experiments for statistical validation

Biological Interpretation Guidelines:

Technical Factors Affecting Band Intensity:

Complex Pattern Interpretation:

• Multiple bands near the expected 53 kDa size may represent different cleavage products or post-translational modifications

• Verify specificity of additional bands using peptide competition assays

• Compare patterns across different experimental conditions to identify consistent vs. variable bands

By integrating these quantitative approaches with biological context, researchers can derive meaningful interpretations from variations in cleaved MMP17 band intensities across experimental conditions.

What are the implications of detecting cleaved MMP17 in different experimental contexts?

The detection of cleaved MMP17 using the Cleaved-MMP17 (Q129) Antibody carries distinct implications depending on the experimental context, providing insights into both normal physiological processes and pathological conditions:

In Cell Culture Systems:

• Drug Response Studies:

  • Detection of increased cleaved MMP17 following etoposide treatment (as demonstrated in A549 cells ) suggests a potential link between DNA damage responses and MMP17 activation

  • Monitoring cleaved MMP17 may serve as a biomarker for cellular response to chemotherapeutic agents

  • Changes in MMP17 cleavage patterns across different drug treatments may reveal pathway-specific regulation mechanisms

• Cell Differentiation Models:

  • Alterations in cleaved MMP17 during differentiation processes may indicate roles in tissue remodeling and cellular maturation

  • Temporal patterns of MMP17 activation could mark specific stages of differentiation

  • Comparison between stem cells and differentiated cells may reveal developmental roles

• Cell Migration and Invasion Assays:

  • Given MMP17's role in extracellular matrix degradation, particularly fibrin , elevated levels of cleaved MMP17 may correlate with enhanced invasive capacity

  • Spatial distribution of cleaved MMP17 at leading edges might indicate localized matrix remodeling during migration

In Tissue Specimens:

• Tumor vs. Normal Tissue:

  • MMP17 is expressed in breast cancer tissues , and differential levels of cleaved MMP17 between tumor and adjacent normal tissue may reflect cancer-specific activation

  • Patterns across tumor grades or stages could provide prognostic indicators

  • Co-localization with other markers might identify specific tumor microenvironments with active matrix remodeling

• Inflammatory Conditions:

  • Given MMP17's ability to cleave pro-TNF-alpha , detection of cleaved MMP17 in inflammatory tissues may indicate active inflammatory signaling

  • Correlations with inflammatory cell infiltration could suggest immune cell-derived MMP17 activation

  • Therapeutic interventions targeting inflammation might be monitored through changes in cleaved MMP17 levels

• Developmental Studies:

  • Expression in organs like brain, colon, ovary, and testis suggests tissue-specific developmental functions

  • Temporal activation patterns during organogenesis might reveal critical periods of MMP17 function

In Disease Models:

• Cancer Models:

  • MMP17 "may be involved in tumoral process" , suggesting cleaved MMP17 detection could serve as a marker for active tumor progression

  • Correlation with metastatic potential might establish cleaved MMP17 as a prognostic indicator

  • Response to targeted therapies might be reflected in altered MMP17 activation patterns

• Neurodegenerative Conditions:

  • Given expression in brain tissues , altered cleaved MMP17 levels might reflect pathological processes in neurodegeneration

  • Potential roles in blood-brain barrier maintenance or remodeling could be investigated through cleaved MMP17 detection

• Fibrotic Disorders:

  • As an enzyme involved in extracellular matrix remodeling, cleaved MMP17 levels might reflect active fibrogenesis or fibrolysis

  • Therapeutic responses in fibrotic disease models could be monitored through changes in MMP17 activation status

The biological significance of cleaved MMP17 detection underscores the importance of using specific antibodies like Cleaved-MMP17 (Q129) Antibody to distinguish the active form from total protein levels, providing more nuanced insights into the functional state of this enzyme across diverse experimental contexts.

How does MMP17 cleavage relate to its biological activity?

The cleavage of MMP17 represents a critical regulatory step that directly impacts its enzymatic activity and biological functions. Understanding this relationship provides essential context for interpreting experimental data obtained using the Cleaved-MMP17 (Q129) Antibody:

Molecular Mechanism of Activation:

MMP17 is synthesized as an inactive zymogen (pro-MMP17) that requires proteolytic processing for activation. This activation involves:

• Cysteine Switch Mechanism:

  • In the pro-form, a conserved cysteine in the cysteine-switch motif binds to the catalytic zinc ion, inhibiting enzymatic activity

  • Proteolytic cleavage disrupts this interaction, releasing the cysteine from the zinc ion

  • This dissociation activates the enzyme by making the catalytic site accessible to substrates

• Furin-Mediated Processing:

  • MMP17 undergoes proteolytic processing by furin endopeptidase

  • This cleavage occurs in the secretory pathway, allowing for the delivery of already activated MMP17 to the cell surface

Correlation Between Cleavage and Activity:

The cleaved form of MMP17 detected by the Cleaved-MMP17 (Q129) Antibody correlates strongly with biological activity:

Functional Consequences of MMP17 Activation:

• Extracellular Matrix Degradation:

  • Activated MMP17 can degrade fibrin and potentially other matrix components

  • This activity contributes to tissue remodeling, wound healing, and potentially pathological matrix degradation

• Processing of Bioactive Molecules:

  • Cleaved MMP17 can process pro-TNF-alpha at the 74-Ala-|-Gln-75 site

  • This processing may activate inflammatory signaling cascades

  • Other membrane-bound precursors of growth factors might similarly be activated by cleaved MMP17

• Cancer Progression:

  • The active form may contribute to tumoral processes

  • Matrix degradation by activated MMP17 could facilitate cancer cell invasion

  • Processing of growth factors by cleaved MMP17 might promote tumor growth

Experimental Assessment of Activity-Cleavage Relationship:

• Activity Assays:

  • Researchers can correlate cleaved MMP17 detection (using the Q129 antibody) with functional assays measuring:

    • Degradation of specific MMP17 substrates

    • TNF-alpha activation in cellular systems

    • Cell invasion through matrix barriers

• Inhibitor Studies:

  • MMP inhibitors should reduce biological activities without affecting detection of the cleaved form

  • Furin inhibitors would be expected to reduce both cleaved MMP17 detection and associated biological activities

• Site-Directed Mutagenesis:

  • Mutations in the catalytic domain would alter activity without affecting cleavage detection

  • Mutations in the cleavage site would prevent both detection by the Q129 antibody and activation

By understanding this direct relationship between cleavage status and biological activity, researchers can use the Cleaved-MMP17 (Q129) Antibody as a proxy for assessing MMP17 activation state, providing valuable insights into the functional role of this enzyme in various experimental and pathological contexts.

What are emerging research areas involving Cleaved-MMP17?

Several promising research directions are emerging around Cleaved-MMP17, offering opportunities for novel discoveries and potential therapeutic applications. The Cleaved-MMP17 (Q129) Antibody serves as a valuable tool for investigating these frontier areas:

Inflammatory Signaling Regulation:

Given MMP17's ability to cleave pro-TNF-alpha at the 74-Ala-|-Gln-75 site , emerging research is exploring:

• The kinetics and specificity of TNF-alpha processing by MMP17 compared to other proteases

• Potential roles in regulating other inflammatory cytokines and chemokines

• Cell type-specific effects of MMP17-mediated inflammatory signaling

• Targeting MMP17 as a novel approach to modulate inflammation in chronic diseases

Cancer Biology and Therapeutic Resistance:

The expression of MMP17 in breast cancer tissues and its potential involvement in tumoral processes suggest important directions:

• Exploring correlations between cleaved MMP17 levels and response to chemotherapeutics like etoposide

• Investigating MMP17's role in cancer stem cell maintenance and therapeutic resistance

• Developing cleaved MMP17 as a biomarker for stratifying patients for specific treatment approaches

• Understanding the relationship between MMP17 activation and tumor microenvironment remodeling

Neural Development and Neurological Disorders:

MMP17's expression in brain tissues opens avenues for neuroscience research:

• Investigating roles in neural development, plasticity, and circuit refinement

• Exploring potential contributions to blood-brain barrier integrity and function

• Examining alterations in MMP17 activation in neurodegenerative diseases

• Studying potential roles in neuroinflammatory conditions where TNF-alpha signaling is implicated

Reproductive Biology:

Expression in ovary and testis tissues suggests unexplored reproductive functions:

• Roles in follicular development and ovulation

• Participation in spermatogenesis and sperm maturation

• Potential involvement in fertilization and early embryo development

• Contributions to reproductive tissue remodeling during the menstrual cycle or pregnancy

Novel Technological Approaches:

Advanced methodologies are enabling deeper investigation of cleaved MMP17:

• Single-cell proteomics to explore cell-to-cell variation in MMP17 activation states

• Live-cell imaging using conformation-sensitive probes to track MMP17 activation in real-time

• CRISPR-mediated genome editing to create precise mutations affecting cleavage sites

• Development of selective inhibitors targeting the cleaved form specifically

Methodological Research Table:

These emerging research directions highlight the importance of specific detection of the cleaved, active form of MMP17 using tools like the Cleaved-MMP17 (Q129) Antibody to advance our understanding of this protease's diverse biological functions.

How might Cleaved-MMP17 be involved in pathological processes?

Cleaved-MMP17, as the active form of this metalloproteinase, has potential involvement in multiple pathological processes across different organ systems. Understanding these pathological roles provides context for research applications of the Cleaved-MMP17 (Q129) Antibody:

Cancer Progression and Metastasis:

MMP17 "may be involved in tumoral process" , with several potential mechanisms:

• ECM degradation facilitating tumor cell invasion through basement membranes

• Activation of growth factors in the tumor microenvironment promoting proliferation

• Processing of cell adhesion molecules affecting cancer cell migration

• Shedding of surface proteins that may alter tumor cell recognition by immune cells

The detection of elevated cleaved MMP17 in breast cancer tissues warrants investigation into:

• Correlation with tumor grade, stage, and patient prognosis

• Association with specific molecular subtypes of breast cancer

• Potential as a therapeutic target or resistance biomarker

• Role in the metastatic cascade, particularly in organs where MMP17 is naturally expressed

Inflammatory Disorders:

Given MMP17's ability to cleave pro-TNF-alpha , its activation may contribute to:

• Chronic inflammatory conditions with TNF-alpha involvement (rheumatoid arthritis, inflammatory bowel disease)

• Acute inflammatory responses following tissue injury

• Leukocyte recruitment and activation, given MMP17 expression in leukocytes

• Inflammatory cascade amplification through additional cytokine processing

Neurodegenerative Diseases:

MMP17 expression in brain tissue suggests potential roles in:

• Blood-brain barrier disruption during neuroinflammation

• Extracellular matrix remodeling affecting neuronal connectivity

• Processing of neural cell adhesion molecules affecting synaptic plasticity

• Amyloid processing or clearance in Alzheimer's disease

• Myelin degradation in demyelinating disorders

Reproductive Pathologies:

Expression in ovary and testis indicates possible involvement in:

• Endometriosis through aberrant tissue remodeling

• Polycystic ovary syndrome through altered follicular development

• Testicular disorders affecting spermatogenesis

• Implantation disorders affecting fertility

Fibrotic Disorders:

As an enzyme involved in matrix remodeling:

• Dysregulated MMP17 activation might contribute to fibrosis progression or resolution

• Imbalance between matrix degradation and deposition in organs like lung, liver, and kidney

• Altered tissue architecture affecting organ function

Pathological Process Correlation Table:

Research utilizing the Cleaved-MMP17 (Q129) Antibody in these pathological contexts could reveal:

• Activation patterns specific to disease states

• Correlation between activation levels and disease severity

• Potential therapeutic windows for targeting MMP17 activation

• Biomarker potential for disease progression or treatment response

Understanding these pathological roles expands the utility of the Cleaved-MMP17 (Q129) Antibody beyond basic research into translational applications with potential clinical relevance.

What experimental approaches can help elucidate the role of MMP17 cleavage in cellular signaling?

Elucidating the role of MMP17 cleavage in cellular signaling requires sophisticated experimental approaches that can capture the dynamic nature of protease activation and its downstream consequences. The following methodologies can be employed with the Cleaved-MMP17 (Q129) Antibody as a key detection tool:

Temporal Signaling Dynamics:

• Time-Course Experiments:

  • Monitor cleaved MMP17 levels at multiple timepoints following stimulation

  • Compare activation kinetics with downstream signaling events

  • Establish temporal relationships between MMP17 cleavage and functional outcomes

• Pulse-Chase Analysis:

  • Track the fate of newly synthesized MMP17 through metabolic labeling

  • Determine half-life differences between cleaved and uncleaved forms

  • Assess compartment-specific processing and turnover rates

• Real-Time Monitoring:

  • Develop FRET-based reporters for MMP17 cleavage events

  • Correlate cleavage detection by antibodies with functional readouts

  • Implement live-cell imaging to visualize activation dynamics

Signaling Pathway Integration:

• Phospho-Proteomics:

  • Compare phosphorylation profiles in systems with normal vs. altered MMP17 cleavage

  • Identify signaling nodes affected by MMP17 activation

  • Establish signaling network maps connecting MMP17 to downstream effectors

• Transcriptional Profiling:

  • Analyze gene expression changes following modulation of MMP17 cleavage

  • Identify transcription factors responsive to MMP17-mediated signaling

  • Perform chromatin immunoprecipitation to establish direct transcriptional effects

• Interactome Analysis:

  • Conduct co-immunoprecipitation with Cleaved-MMP17 (Q129) Antibody

  • Perform mass spectrometry to identify interactors specific to the cleaved form

  • Validate key interactions through complementary approaches

Substrate Identification and Validation:

• Proteomic Approaches:

  • Conduct terminal amine isotopic labeling of substrates (TAILS) to identify cleavage targets

  • Compare substrate profiles between wild-type and MMP17-deficient systems

  • Perform in vitro cleavage assays with recombinant cleaved MMP17

• Candidate Substrate Validation:

  • Beyond TNF-alpha , test other potential substrates

  • Generate cleavage-resistant mutants of confirmed substrates

  • Assess functional consequences of substrate cleavage in cellular contexts

• Spatial Regulation:

  • Investigate co-localization of cleaved MMP17 with potential substrates

  • Determine membrane microdomains enriched for MMP17 activity

  • Assess the impact of altered subcellular targeting on cleavage patterns

Genetic and Pharmacological Manipulation:

Translational Approaches:

• Disease Model Systems:

  • Compare MMP17 cleavage patterns across relevant pathological models

  • Correlate with disease-specific signaling alterations

  • Test therapeutic interventions targeting the MMP17 activation axis

• Patient-Derived Materials:

  • Analyze cleaved MMP17 in patient samples using the Q129 antibody

  • Correlate with clinical parameters and treatment responses

  • Establish potential as a biomarker for aberrant signaling pathway activation

• Therapeutic Development:

  • Screen for compounds that modulate MMP17 cleavage

  • Develop targeted approaches based on cleavage-dependent interactions

  • Explore combination strategies targeting both MMP17 and downstream signaling nodes

By integrating these experimental approaches, researchers can build a comprehensive understanding of how MMP17 cleavage contributes to cellular signaling networks across physiological and pathological contexts, with the Cleaved-MMP17 (Q129) Antibody serving as a critical tool for specifically detecting the active form of this important regulatory enzyme.